Mehmet Gokhan Culha, Mehmet Ali Sezgin, Mustafa Erkoc, Eyyup Danis, Emre Can Polat, Alper Otunctemur
{"title":"Efficacy of Mirabegron and Propiverine Combination in the Treatment of Refractory Overactive Bladder.","authors":"Mehmet Gokhan Culha, Mehmet Ali Sezgin, Mustafa Erkoc, Eyyup Danis, Emre Can Polat, Alper Otunctemur","doi":"10.1007/s00192-025-06178-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and hypothesis: </strong>The aim of this study is to evaluate the effectiveness and safety of mirabegron + propiverine combination in the treatment of overactive bladder (OAB) resistant to anticholinergic agent or beta-3 agonist treatment.</p><p><strong>Method: </strong>Patients who presented with OAB symptoms between March 2019 and August 2023 and did not respond to anticholinergic or beta-3 agonist treatment were included in the study. All patients were recommended to use mirabegron 50 mg (Betmiga, Astellas Pharma, Japan) and propiverine 30 mg (Mictonorm SR, 30 mg, Recordati Pharmaceuticals, Italy) once a day. Patients' symptoms were evaluated with OABSS and bladder diary 3 months after treatment. Side effects and satisfaction rates were recorded.</p><p><strong>Results: </strong>A total of 320 patients were included in the study. One-year data of a total of 264 patients were examined. After 1 year of treatment, the patients' OABSS score, mean daily micturition frequency according to the bladder diary, frequency of urge incontinence, nocturia, and number of pads decreased compared to before treatment (p < 0.001 for each). After 1 year, 62.1% (164/264) of patients benefited from the mirabegron + propiverine combination. The most common side effects were dry mouth in 43 patients (16.3%) and constipation in 59 patients (22.3%).</p><p><strong>Conclusion: </strong>Mirabegron + propiverine treatment is an effective and reliable treatment option in the treatment of OAB resistant to medical monotherapy. With this combination treatment to be used before botulinum toxin application in the treatment of resistant OAB, the number of patients who will receive Botox may decrease.</p>","PeriodicalId":14355,"journal":{"name":"International Urogynecology Journal","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Urogynecology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00192-025-06178-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and hypothesis: The aim of this study is to evaluate the effectiveness and safety of mirabegron + propiverine combination in the treatment of overactive bladder (OAB) resistant to anticholinergic agent or beta-3 agonist treatment.
Method: Patients who presented with OAB symptoms between March 2019 and August 2023 and did not respond to anticholinergic or beta-3 agonist treatment were included in the study. All patients were recommended to use mirabegron 50 mg (Betmiga, Astellas Pharma, Japan) and propiverine 30 mg (Mictonorm SR, 30 mg, Recordati Pharmaceuticals, Italy) once a day. Patients' symptoms were evaluated with OABSS and bladder diary 3 months after treatment. Side effects and satisfaction rates were recorded.
Results: A total of 320 patients were included in the study. One-year data of a total of 264 patients were examined. After 1 year of treatment, the patients' OABSS score, mean daily micturition frequency according to the bladder diary, frequency of urge incontinence, nocturia, and number of pads decreased compared to before treatment (p < 0.001 for each). After 1 year, 62.1% (164/264) of patients benefited from the mirabegron + propiverine combination. The most common side effects were dry mouth in 43 patients (16.3%) and constipation in 59 patients (22.3%).
Conclusion: Mirabegron + propiverine treatment is an effective and reliable treatment option in the treatment of OAB resistant to medical monotherapy. With this combination treatment to be used before botulinum toxin application in the treatment of resistant OAB, the number of patients who will receive Botox may decrease.
期刊介绍：
The International Urogynecology Journal is the official journal of the International Urogynecological Association (IUGA).The International Urogynecology Journal has evolved in response to a perceived need amongst the clinicians, scientists, and researchers active in the field of urogynecology and pelvic floor disorders. Gynecologists, urologists, physiotherapists, nurses and basic scientists require regular means of communication within this field of pelvic floor dysfunction to express new ideas and research, and to review clinical practice in the diagnosis and treatment of women with disorders of the pelvic floor. This Journal has adopted the peer review process for all original contributions and will maintain high standards with regard to the research published therein. The clinical approach to urogynecology and pelvic floor disorders will be emphasized with each issue containing clinically relevant material that will be immediately applicable for clinical medicine. This publication covers all aspects of the field in an interdisciplinary fashion
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
